摘要
目的分析替加环素影响重症感染患者纤维蛋白原(FIB)水平的相关危险因素。方法选取接受替加环素治疗的重症感染患者,根据用药期间FIB检测结果将患者分为试验组(FIB<2.0 g·L^-1)和对照组(FIB≥2.0 g·L^-1),统计患者的临床资料,分析替加环素致FIB降低的危险因素。结果最终纳入研究患者共72例,其中试验组41例,对照组31例。相关性分析发现,重症感染患者FIB降低与替加环素用药时间及腹腔感染相关(P<0.05),而2组患者在基础疾病、伴有黄疸或出血等其他病症、其他感染部位、替加环素初始剂量、维持剂量、合并用头孢哌酮钠舒巴坦钠或丙戊酸钠以及不同病原菌感染等方面的比较差异均无统计学意义(均P>0.05)。试验组中,88.46%(23例/26例)的患者在停用替加环素后FIB水平恢复正常,平均时间为(5.04±2.87)d。结论替加环素致重症感染患者FIB水平降低的高危险因素为替加环素用药时间及腹腔感染,故治疗中应尽量缩短替加环素的使用时间及预防腹腔感染,并密切监测FIB水平的变化。
Objective To analyze the related risk factors of tigecycline affecting fibrinogen(FIB)levels in patients with severe infection.Methods Severe infections patients were selected.According to the FIB test results during the medication period,the patients were divided into treatment group(FIB<2.0 g·L^-1)and control group(FIB≥2.0 g·L^-1).The clinical data were collected and the risk factors of FIB reduction induced by tigecycline were analyzed.Results A total of 72 patients were enrolled in the study(41 in treatment group and 31 in control group).The correlation analysis showed that the decrease of FIB in patients with severe infections was related to the time of tigecycline administration and abdominal infection(P<0.05),while there was no significant difference between the two groups in terms of basic diseases,other diseases such as jaundice or hemorrhage,other infection sites,initial dose of tigecycline,maintenance dose,combined use of cefoperazone sodium,sulbactam sodium or valproate sodium,and infection of different pathogens(P>0.05).In treatment group,88.46%(23 cases/26 cases)of the patients were recovered to normal FIB level after discontinuation of tigecycline,mean time was(5.04±2.87)d.Conclusion The high risk factors for the decrease of FIB level in patients with severe infection caused by tigecycline are the medication time of tigecycline and abdominal infection,which indicate that the medication time of tigecycline should be shortened and the abdominal infection should be prevented as soon as possible in the treatment,and the changes of FIB level should be closely monitored.
作者
张青贵
方强
胡娟
童武华
朱康元
ZHANG Qing-gui;FANG Qiang;HU Juan;TONG Wu-hua;ZHU Kang-yuan(Intensive Care Unit,First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310003,Zhejiang Province,China;Intensive Care Unit,Jiaxing Maternal and Child Health Hospital,Jiaxing 314000,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第2期99-102,共4页
The Chinese Journal of Clinical Pharmacology
